Carnegie Mellon Researcher Raises $35M for Clinical Intelligence Work

Unite.AI
Read full story· 3 min
Carnegie Mellon researcher raised $35M to develop Xlue's clinical intelligence model that predicts health changes and simulates treatment outcomes. The model uses health states rather than tokens, improving prediction accuracy and efficiency. It aims to aid drug trial design and preventive care through simulation and prospective studies.

What happened

On November 18, 2026, Xlue announced that a researcher from Carnegie Mellon had secured $35 million to advance its clinical intelligence model. The company also released a technical report detailing its new health foundation model, which is designed to predict changes in patient health and simulate the effects of treatments. The model represents patient health as evolving states rather than sequences of tokens, aiming to help physicians and scientists explore potential outcomes before making decisions. Xlue is applying this technology in collaborations with hospitals and pharmaceutical companies, focusing on drug trial design and preventive care studies.

Key details

  • $35 million was raised for the project.
  • The announcement and technical report were both released on November 18, 2026.
  • Xlue's model uses health states instead of tokens to represent patient trajectories.
  • In blind third-party tests, the model outperformed leading token-based models at less than 0.1% of the compute cost.

Why it matters

Hospitals, drug developers, and pharmaceutical companies now have access to a tool that can model patient health and simulate treatment outcomes more efficiently and accurately than previous approaches. This could reduce the cost and risk of designing drug trials and help identify new uses for existing medicines. Patients may benefit from improved preventive care and more personalized treatment planning as the model is tested in real-world clinical settings.


More in Healthcare